Home Care Pharmacy of Palm Coast Inc., Palm Coast, FL
Is Home Care Pharmacy of Palm Coast Inc. registered with the FDA as a 503B outsourcing facility?
No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels it a 503A facility.
Does Home Care Pharmacy of Palm Coast Inc. hold a Florida pharmacy license?
The Florida Board of Pharmacy lists license PH27614 for HOME CARE PHARMACY OF PALM COAST, INC., PALM COAST, status Disc Relinquish, as of Nov 15, 2026.
Has Home Care Pharmacy of Palm Coast Inc. had a state board action or FDA letter?
FDA letters: record found. FDA’s compounding inspections and actions page, current as of Oct 22, 2026, lists 1 untitled letter (May 4, 2020) for Home Care Pharmacy of Palm Coast Inc. State board actions: record found. The Florida Board of Pharmacy’s enforcement list for pharmacy permits lists 2 actions: “Voluntary Surrender” dated Feb 28, 2018, case 201531480 on license PH27614 and “Administrative Complaint Filed” dated Sep 7, 2017, case 201531480 on license PH27614.
FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.
- Names in FDA records
- Home Care Pharmacy of Palm Coast Inc.
- Location
- Palm Coast, FL
- Type as FDA labels it
- 503A
- FDA 503B list
- No matching record found
- Form 483s on FDA’s actions page
- 0
- Warning letters on FDA’s actions page
- 0
- Latest action on that page
- May 4, 2020
- FDA Data Dashboard inspections
- 2 inspections: 1 OAI, 1 VAI; 2 published Form 483s
- Form 483 text on this page
- 1 Form 483, 7 observations
- State board records
- License found: PH27614, Disc Relinquish
FDA inspections and letters
FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as Home Care Pharmacy of Palm Coast Inc., a 503A facility, with 1 dated action.
| Document | |||
|---|---|---|---|
| May 4, 2020 | Untitled letter | Untitled Letter Issued 05/04/2020 | FDA copy (archived) |
An untitled or FMD-145 letter states FDA’s view when it was issued.
FDA inspection classifications and published Form 483s
The FDA Data Dashboard, read Nov 15, 2026, lists Home Care Pharmacy of Palm Coast, Inc., Palm Coast, FL (FEI number 3006899675), matched to this page by exact name, city and state. It lists 2 inspections: 1 OAI, 1 VAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.
| Inspection ended | Classification | Project area and product type | FEI | Inspection ID |
|---|---|---|---|---|
| Apr 25, 2018 | Voluntary Action Indicated (VAI) | Drug Quality Assurance (Drugs) | 3006899675 | 1049518 |
| May 25, 2016 | Official Action Indicated (OAI) | Drug Quality Assurance (Drugs) | 3006899675 | 973463 |
Form 483s FDA has published for this site
- May 31, 2018: Form 483 to Home Care Pharmacy of Palm Coast, Inc., published Jan 17, 2024. fda.gov
- Jun 17, 2016: Form 483 to Home Care Pharmacy of Palm Coast, Inc., published Jan 17, 2024. fda.gov
FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.
Form 483 observations
A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.
FDA’s published Form 483 for this site has 7 numbered observations in all. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.
Inspection May 17, 2016 to May 25, 2016: 7 observations
- Firm on the cover
- , Palm Coast, FL 32 137- 3891 Type esta bli shment i nspected Producer of Sterile Drugs
- FEI number
- 3006899675
- FDA district office on the cover
- 555 Winderly place, suite 200 maitland, fl 32751
- Matched to this page by
- FEI number on the cover; linked from Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
This 483 is a scanned image. The text below is the PDF’s own text layer, which can misread characters; the PDF is the record.
Observation 1
Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the room and equipment to produce aseptic conditions.
Specifically,
A. On 05/17/2016, I observed your firm's technician cleaning the ISO 5 re dacted b4, whi ch w as red acted b4 and the redacted b4. During this clean ing, the technician did not follow procedure "Germfree redacted b4 " SOP 3.020 which specifies to per form th e cle aning process with redacted b 4. Inste ad the te chnician cleaned the ISO 5 area w ith reda cted (b) (4) cleanings. In addition, the technician was not wearing any sterile gowning items during this cleaning. The technician had expo sed h air t hat touc hed the sleev es, glov es, and other pa rts of the IS O 5 a rea dur ing the cleaning process. Furthermore, during the cleaning of the ISO 5 area your firm used non-ster ile wipes which are stored open in the ISO 8 area.
B. Your firm does not use a sporicidal agent during cleaning of the ISO 5 areas. Per your Pha rmacist In-Charge (PIC) the chemicals used to clean are Sterile red acted b4
. Furthermore, application times o f the cleaning solutions ar e are not wel l defined in the proc edure. ...
Observation 2
Aseptic processing areas are deficient regarding the system for monitoring environmental conditions. • Specifically,
Per your procedure "Quality Assurance Program" SOP 9.8 and PIC, environmental monitoring of the ISO 5 area and operators gloves is done redacted b4 · During the time between th e redact ed b4 monitoring periods there are no red acted b4 activities being performed during pr oduction of ster ile drug p roducts. In a dditio n, the re is no form of daily mo nitorin g of t he ISO 5 a rea. For example , dur ing t his tim e p eriod no air mon itoring, surface sampling, glove s ampling, or par ticulate sampling is being performed.
Observation 3
Clothing of personnel engaged in the manufacturing and processing ofdrug products is not appropriate
for the duties they perform.
Specifically,
On 05/ 17/2016, I observed cleaning of the ISO 5 area during this time the technician wore only non- sterile gloves and a non-sterile face mask, no gowning was worn to prevent particulate shedding and maintain the sterility of the ISO 5 area. For example, the technician was not wearing any sterile hair
nets, gowns, gloves or shoe covers.
Observation 4
Each batch of drug product purporting to be sterile and pyrogen-free is not laboratory tested to determine conformance to such requirements.
Specifically,
On 05/23/2016, your PIC stated that testing of endotoxin levels and bioburden of sterile drug products is only done re dacted b 4. Review of testing results shows only redacted b4 non-sterile to sterile products are being actively assessed for endotoxin levels or bioburden. Your firm produces the following sterile products from non-sterile components .
• Alprostadil 100 mcg/ml/redacted b4 (PGEl) • • Papaverine HCL 30 mg/mL/ Phetolamine Mesylate 1.5 mg/mL injection Solution (Bi-Mix) • Alprostadil 10 meg/Papaverine HCL 30 mg/Phentolamine Mesylate 0.5 mg/tnL Injection
Solutwn ('Iri -Mix) • Dexamethasone Sodium Phosphate • Papaverine HCL 18.9 mg/mL/Phentolamine Mesylate 0.9 mg/mL/ Atropine Sulfate 0.18
mg/ mL/Alprostadil 9 mcg/mL Injection Solution (Quad- Mix) • Droperidol2.5 mg/mL Injection Solution • Glutathione 200 mg/mL Injection Solution • Hydroxocobalamin 10 mg/mL Injection Solution • Sodium Hydroxide 0.1 N red acted b4
• • • J
Observation 5
Written records arc not made of investigations into unexplained discrepancies.
Specifically,
A. On re dacted b 4, your technician had positive growth during media fill testing, yet there is no record of investigation or retesting. A note on the test record says “possible vial contamination” , ho wever, no further information is provided in support of the finding or impact to products using th e same lot of vials. Fu rthermore, this media fill was considered as a passing media fill.
B . On 05/18/2016, I observed your technician perform a re dacted b 4 test which
rk the product with an "X" and remake the order. The PTC was not noti fied until after the product was remade and redacted b4 test passed.
Observation 6
The batch production and control records are deficient in that they do not include documentation of the accomplishment of each significant step in manufacturing and processing.
Specifically,
On 05/24/2016, I requested the production records for prescription number redacted b6 and redacted b6. Your PIC was unable to locate the records associated with this aseptically produced drug product. A logbook is used to record production of sterile products; this logbook does not contain the records for either prescription requested.r (b) (6) 1On 05/24/2016, I requested the production records for prescription number redacted b6 and redacted b6. Your PIC was unable to locate the records associated with this aseptically produced drug product. A logbook is used to record production of sterile products; this logbook does not contain the records for either prescription requested.(b)(6) 1On 05
/24/2016, I requested the production records for prescription number redacted b6 and redacted b6. Your PIC was unable to locate the records associated with this aseptically produced drug product. ...
Observation 7
Aseptic processing areas are deficient regarding air supply that is filtered through high-efficiency particulate air filters under positive pressure.
Specifically,
The ISO 8 room in-which the ISO 5 re dacted b4 is located, does not have HEP A filter units at the air supply vents for the area. The filter located in the return air grate is not sufficient to ensure adequate
filtration of the air circulating through the area.
Linked 483s whose text is not shown
- May 31, 2018: FDA document 113688: the FEI number and firm name on its cover do not match this page by the rule.
State board of pharmacy records
The Florida Board of Pharmacy file dated Nov 15, 2026 lists these licenses under the same name, city and state as this pharmacy. Board file.
| License | Type as the board gives it | Name on the board record | City | Status |
|---|---|---|---|---|
| PH27614 | Pharmacy | HOME CARE PHARMACY OF PALM COAST, INC. | PALM COAST | Disc Relinquish |
Board actions
As the board words them, newest first. An entry that is a complaint, charge or notice the board filed is a charge, not a final decision; only an order or final action records the outcome.
- Feb 28, 2018: “Voluntary Surrender”, license PH27614, case 201531480, HOME CARE PHARMACY OF PALM COAST INC., PALM COAST, FL. Board list
- Sep 7, 2017: “Administrative Complaint Filed”, license PH27614, case 201531480, HOME CARE PHARMACY OF PALM COAST INC., PALM COAST, FL. Board list
What this covers: Every enforcement action the Florida Department of Health lists for Board of Pharmacy pharmacy permits, worded as the department gives it. The list includes administrative complaints filed as well as final actions, and links no documents. An administrative complaint is an allegation the department has filed, not a finding. Actions in the data are dated Sep 19, 1980 to Nov 10, 2026.
Close but not exact board records
These board records share a name with this pharmacy but did not meet this index’s matching rule (same name, same city, same state), so they are not treated as its license. They may belong to a separate business.
- License PH10063, HM CARE PHAR OF PALM COAST INC (dba HOME CARE PHARMACY), PALM COAST, status Clear: same city, one name is a longer form of the other.
This page restates FDA’s lists and state board of pharmacy records. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.
Sources
- FDA: Compounding: Inspections, Recalls, and other Actions
- FDA Registered Outsourcing Facilities (503B)
- FDA Data Dashboard: inspection classifications and published Form 483s
- FDA: FDA Form 483 Frequently Asked Questions
- Florida Board of Pharmacy license file
- Florida Board of Pharmacy disciplinary records
Records last pulled Nov 15, 2026. Every entry links to the original public record.